We describe an ex-premature infant presenting with SARS-CoV-2 infection in the 5th week of life. Current reports indicate that acute symptomatic SARS-CoV-2 infection is relatively rare and much less severe than in adults. This case highlights that infection can be associated with life threatening pulmonary disease in young infants and that infection can follow a similar disease course to that described in adults. We provide first data on the use of the novel antiviral remdesivir in a young child and an innovative approach to expedited approval from a multidisciplinary clinical team and bioethics committee for compassionate access to the drug.
Read the full article here.